+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Complement C5 Recombinant Monoclonal Antibody Market by Application (Diagnostic, Research Use, Therapeutic), Product Type (IgG1, IgG2, IgG3), End User, Research Area - Global Forecast 2025-2030- Product Image
Complement C5 Recombinant Monoclonal Antibody Market by Application (Diagnostic, Research Use, Therapeutic), Product Type (IgG1, IgG2, IgG3), End User, Research Area - Global Forecast 2025-2030- Product Image
New

Complement C5 Recombinant Monoclonal Antibody Market by Application (Diagnostic, Research Use, Therapeutic), Product Type (IgG1, IgG2, IgG3), End User, Research Area - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118833
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Complement C5 recombinant monoclonal antibodies have emerged as transformative agents in modern biomedical research and clinical practice. These highly specific protein constructs target the fifth component of the complement system, enabling precise modulation of immune pathways implicated in a broad range of disease processes. As molecular understanding deepens, these antibodies have transitioned from experimental curiosities to indispensable tools, shaping investigational approaches and informing therapeutic strategies.

Over the past decade, advancements in recombinant technology have refined the production and structural optimization of complement C5 antibodies. Such improvements have enhanced binding affinity, stability, and manufacturability, driving greater consistency and potency in both in vitro assays and clinical formulations. Consequently, research laboratories and diagnostic developers have increasingly integrated these reagents into workflows aimed at elucidating complement-mediated mechanisms and developing novel diagnostics. The evolution of complement C5 antibodies underscores a convergence of molecular innovation, rigorous validation, and translational applicability-laying the groundwork for next-generation interventions that harness the complement cascade with unprecedented specificity.

Identifying the Emerging Innovations and Collaborative Trends That Are Transforming the Complement C5 Recombinant Monoclonal Antibody Landscape

The realm of complement C5 recombinant monoclonal antibodies is witnessing pivotal shifts that are redefining research paradigms and therapeutic prospects. Initially regarded as niche reagents for probing complement activation, these antibodies are now central to a broader spectrum of investigative and clinical endeavors, catalyzed by innovations in engineering and a deeper appreciation of complement biology.

In research settings, the transition toward multifunctional antibody formats has unlocked novel applications, from high-throughput screening platforms to multiplexed imaging assays. Meanwhile, diagnostic developers are leveraging refined antibody specificity to create companion diagnostics that guide personalized treatment decisions, moving beyond traditional in vitro applications. Equally significant is the therapeutic landscape, where bispecific constructs and antibody fragments tailored to deliver targeted payloads or modulate complement activity in select tissues are gaining traction.

These transformative shifts are underscored by an intensification of collaborative efforts between academia, biotech innovators, and regulatory authorities. As standards for antibody characterization and validation become more stringent, the industry is coalescing around best practices that prioritize reproducibility and clinical relevance, ensuring that complement C5 antibodies will continue to evolve in tandem with emerging scientific and regulatory frameworks.

Assessing the Multifaceted Effects of United States Tariffs Implemented in 2025 on Complement C5 Recombinant Monoclonal Antibody Supply Chains and Cost Dynamics

The imposition of new United States tariffs in 2025 has introduced complexities in the global supply chain for complement C5 recombinant monoclonal antibodies. Given the intricate manufacturing processes often reliant on specialized reagents and bioprocessing equipment, import duties have amplified cost considerations for research institutions, diagnostic developers, and biopharmaceutical manufacturers alike.

Manufacturers have responded by diversifying sourcing strategies, seeking alternative production hubs, and reinforcing domestic capacity to mitigate tariff exposure. Simultaneously, distributors have optimized inventory models to account for extended lead times and increased landed costs, ensuring continuity of supply for critical research and clinical applications. Although these measures have generated localized cost pressures, they have also spurred investments in automation and process efficiencies that may yield long-term resilience.

Looking ahead, industry stakeholders are monitoring potential policy shifts and negotiating tariff exclusions for key bioreagents. These efforts reflect a broader recognition of the complement antibody sector’s strategic importance to national healthcare priorities and biomedical innovation. In the interim, adaptive sourcing, collaborative procurement, and enhanced supply chain transparency remain paramount to sustaining development and deployment of complement C5 recombinant monoclonal antibodies under the new tariff regime.

Unveiling Deep Segmentation Insights Across Applications Product Types End Users and Research Areas Driving Complement C5 Recombinant Monoclonal Antibody Demand

A nuanced understanding of market segmentation reveals diverse drivers shaping demand for complement C5 recombinant monoclonal antibodies across various applications, product types, end users, and research areas. When examining the market through the lens of application, diagnostic usage divides between companion diagnostics and in vitro diagnostics while research applications encompass both clinical research and preclinical research, each with distinct validation and regulatory requirements.

Considering product types, the presence of IgG1, IgG2, IgG3, and IgG4 subclasses offers differentiated effector functions and pharmacokinetics, fostering tailored reagent selection based on assay sensitivity needs or therapeutic design preferences. Furthermore, end users span academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotech companies, each segment presenting unique procurement cycles, quality benchmarks, and partnership models.

Finally, in the realm of research areas, complement C5 antibodies are deployed to investigate autoimmune disorders, infectious diseases, neurological disorders, and oncology, underscoring the technology’s versatility. Through this multifaceted segmentation approach, stakeholders can pinpoint priority submarkets, optimize resource allocation, and align product development with specific end-user and disease-area requirements.

Analyzing Regional Dynamics Influencing Complement C5 Antibody Adoption and Research Investment Across Americas Europe Middle East Africa and Asia Pacific

Geographic dynamics play a critical role in shaping the trajectory of complement C5 recombinant monoclonal antibodies, as regional variations in healthcare infrastructure, regulatory environments, and research investment influence adoption patterns. In the Americas, robust funding for academic research and a mature biopharma sector fuel both early-stage and late-stage development activities, with leading institutions and contract organizations collaborating on advanced complement studies.

Across Europe Middle East and Africa, a complex regulatory mosaic presents both challenges and opportunities, as diverse approval pathways incentivize local manufacturing partnerships and foster translational research networks. Key markets in Western Europe benefit from established diagnostic frameworks and public-private consortia, driving precision medicine initiatives that integrate complement C5 antibodies into companion diagnostic workflows.

Asia-Pacific is emerging as a high-growth zone, underpinned by escalating research budgets in China, Japan, and Australia, as well as expanding clinical trial activity in several Southeast Asian nations. Strategic alliances between regional academic centers and global life science companies are accelerating capacity building and knowledge transfer, positioning this region as a future hub for innovation in complement therapeutics and diagnostics.

Mapping the Competitive Dynamics and Strategic Collaborations Shaping the Complement C5 Recombinant Monoclonal Antibody Ecosystem

The competitive landscape for complement C5 recombinant monoclonal antibodies is characterized by established life science enterprises, emerging biotechnology firms, and niche antibody developers. Many leading life science companies have leveraged extensive biologics expertise to advance high-affinity complement C5 reagents through rigorous validation workflows. Meanwhile, innovative biotech startups are carving out specialized niches, focusing on novel antibody formats or bespoke engineering approaches that enhance target specificity and functional versatility.

Collaborative alliances have become a strategic imperative, with research-driven partnerships facilitating co-development of proprietary antibody panels and joint commercialization initiatives. Contract research organizations are also evolving, integrating end-to-end antibody services that span custom generation, analytical characterization, and assay development, thereby meeting the escalating demands of pharmaceutical and diagnostic end users for turnkey solutions.

This competitive interplay underscores a dynamic ecosystem where differentiation hinges on robust intellectual property portfolios, scalable manufacturing capabilities, and the ability to navigate evolving regulatory frameworks. Stakeholders that combine technological innovation with strategic partnerships will be well positioned to capture emerging opportunities in both research markets and clinical diagnostics.

Delivering Actionable Strategies for Industry Stakeholders to Accelerate Development Collaboration and Market Penetration in Complement C5 Antibody Innovations

Industry leaders seeking to capitalize on the complement C5 antibody revolution should adopt a multifaceted approach that balances innovation, collaboration, and operational excellence. First, prioritizing investment in advanced engineering platforms can accelerate the development of next-generation antibody formats, including bispecific constructs and fragment-based modalities, which offer differentiated functional profiles.

Second, forging strategic partnerships with academic institutions and specialized contract research organizations can streamline early-stage validation and reduce time-to-market. Such alliances also facilitate access to diverse specimen repositories and clinical cohorts, enhancing translational relevance. Third, strengthening supply chain resilience through dual sourcing strategies and regional manufacturing hubs ensures continuity in the face of policy changes or logistic disruptions.

Finally, aligning regulatory and quality management frameworks across geographies, and engaging proactively with health authorities, can preempt potential barriers and expedite product approvals. By integrating these initiatives into a coherent strategic roadmap, industry leaders will be empowered to harness the full potential of complement C5 recombinant monoclonal antibodies across research, diagnostic, and therapeutic domains.

Outlining a Comprehensive Mixed Methods Research Framework Combining Primary Interviews and Secondary Data to Ensure Robust Insights into Complement C5 Antibodies

This report employs a rigorous research methodology combining primary and secondary sources to deliver an authoritative analysis of the complement C5 recombinant monoclonal antibody landscape. Secondary research included peer-reviewed journals, patent filings, regulatory submissions, and conference proceedings to establish a robust foundational understanding of technical advancements, clinical applications, and market dynamics.

Primary research comprised in-depth interviews with key opinion leaders, antibody developers, contract research organizations, and diagnostic manufacturers to validate findings and capture nuanced insights regarding strategic priorities, adoption challenges, and emerging opportunities. Data triangulation ensured consistency across sources, while qualitative and quantitative analyses were integrated to contextualize trends and delineate regional distinctions.

Throughout the process, strict adherence to methodological best practices-including detailed source documentation, systematic peer reviews, and continuous data quality checks-ensured the reliability and relevance of the research. This comprehensive approach provides a transparent and replicable framework for stakeholders seeking to navigate the complexities of complement C5 monoclonal antibody development and application.

Summarizing the Strategic Implications and Emerging Opportunities in Complement C5 Recombinant Monoclonal Antibody Development

In summary, complement C5 recombinant monoclonal antibodies are poised to redefine both fundamental research and clinical paradigms by offering unparalleled specificity in modulating immune pathways. Technological advancements, evolving regulatory landscapes, and strategic collaborations are collectively driving the maturation of these antibodies from research reagents to critical components of diagnostic and therapeutic arsenals.

As stakeholders navigate the complexities of tariff impacts, regional regulatory nuances, and competitive pressures, a clear strategic focus on innovation, partnership, and supply chain resilience will distinguish market leaders. By leveraging granular segmentation insights and tailored development strategies, organizations can align their portfolios with the most promising application areas and end-user requirements.

Ultimately, the synthesis of rigorous research methodology and actionable recommendations presented herein equips decision-makers with the insights needed to capitalize on the burgeoning opportunities within the complement C5 antibody ecosystem.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Application
    • Diagnostic
      • Companion Diagnostics
      • In Vitro Diagnostics
    • Research Use
      • Clinical Research
      • Preclinical Research
    • Therapeutic
  • Product Type
    • IgG1
    • IgG2
    • IgG3
    • IgG4
  • End User
    • Academic & Research Institutes
    • Contract Research Organizations
    • Diagnostic Laboratories
    • Pharmaceutical & Biotech Companies
  • Research Area
    • Autoimmune Disorders
    • Infectious Diseases
    • Neurological Disorders
    • Oncology
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • AstraZeneca PLC
  • InflaRx N.V.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of complement C5 monoclonal therapies into combination treatment regimens for rare immune disorders
5.2. Emergence of biosimilar alternatives to established C5 inhibitors driving competitive pricing pressure
5.3. Growing adoption of subcutaneous complement C5 antibody formulations to enhance patient convenience and adherence
5.4. Innovative engineering of next generation C5 recombinant antibodies to improve safety and reduce dosing frequency
5.5. Expansion of complement C5 antibody therapeutic indications into neuroinflammatory and renal disease markets
5.6. Impact of manufacturing challenges on global supply and pricing of high-value C5 monoclonal therapies
5.7. Strategic collaborations between biotech innovators and pharmaceutical giants accelerating C5 inhibitor development pipelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Complement C5 Recombinant Monoclonal Antibody Market, by Application
8.1. Introduction
8.2. Diagnostic
8.2.1. Companion Diagnostics
8.2.2. In Vitro Diagnostics
8.3. Research Use
8.3.1. Clinical Research
8.3.2. Preclinical Research
8.4. Therapeutic
9. Complement C5 Recombinant Monoclonal Antibody Market, by Product Type
9.1. Introduction
9.2. IgG1
9.3. IgG2
9.4. IgG3
9.5. IgG4
10. Complement C5 Recombinant Monoclonal Antibody Market, by End User
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Contract Research Organizations
10.4. Diagnostic Laboratories
10.5. Pharmaceutical & Biotech Companies
11. Complement C5 Recombinant Monoclonal Antibody Market, by Research Area
11.1. Introduction
11.2. Autoimmune Disorders
11.3. Infectious Diseases
11.4. Neurological Disorders
11.5. Oncology
12. Americas Complement C5 Recombinant Monoclonal Antibody Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Complement C5 Recombinant Monoclonal Antibody Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AstraZeneca PLC
15.3.2. InflaRx N.V.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET: RESEARCHAI
FIGURE 24. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET: RESEARCHSTATISTICS
FIGURE 25. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET: RESEARCHCONTACTS
FIGURE 26. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 90. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 91. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 92. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 93. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 98. CANADA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 99. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 102. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 103. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 106. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 107. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 110. MEXICO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 161. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 164. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 165. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 168. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 169. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 172. GERMANY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 173. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 176. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 177. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 180. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 181. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 184. FRANCE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 197. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 200. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 201. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 202. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 203. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 204. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 205. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 208. ITALY COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 209. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 212. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 213. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 216. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 217. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 220. SPAIN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 257. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 260. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 261. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2024 (USD MILLION)
TABLE 268. DENMARK COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS COMPLEMENT C5 RECOMBINANT MONOCLO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Complement C5 Recombinant Monoclonal Antibody market report include:
  • AstraZeneca PLC
  • InflaRx N.V.

Related Topics

Related Reports

Complement Inhibitors Global Market Report 2025 - Product Image

Complement Inhibitors Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review - Product Image

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

  • Report
  • Global
From
Complement C5 Inhibitors - Pipeline Insight, 2025 - Product Image

Complement C5 Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2025 - Product Image

Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Complement C4 Antibody Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Complement C4 Antibody Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.